NCT06148948已完成1 期
Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BI 1584862 in Japanese Healthy Male Subjects (Single- Masked, Randomised, Placebo-controlled, Parallel Group Design)
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator
研究概览
简要总结
The goal of this trial is to investigate safety, tolerability and pharmacokinetics of BI 1584862 in healthy male subjects of Japanese ethnicity following oral administration of single rising doses.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects according to the assessment of the investigator, as based on a complete medical history including a physical examination, vital signs blood pressure (BP) and pulse rate (PR), 12-lead electrocardiogram (ECG), and clinical laboratory tests at screening visit.
- •Japanese ethnicity, according to the following criteria: born in Japan, have lived outside of Japan <10 years, and have parents and grandparents who are Japanese
- •Age of 18 to 45 years (inclusive) at screening visit.
- •Body mass index (BMI) of 18.5 to 24.9 kg/m^2 (inclusive) at screening visit.
- •Signed and dated written informed consent in accordance with International Conference of Harmonization-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
- •Subjects who agree to minimise the risk of making their partner pregnant by fulfilling any of the following criteria starting from the start of trial medication until 90 days after the last medication:
- •Use of adequate contraception, any of the following methods plus condom: intrauterine device, combined oral contraceptives that started at least 2 months prior to the first drug administration
- •Vasectomized (vasectomy at least 1 year prior to enrolment)
- •Surgical sterilization (including bilateral tubal occlusion, hysterectomy or bilateral oophorectomy) of the subject's female partner
- •Female partner is postmenopausal, defined as no menses for 1 year without an alternative medical cause
排除标准
- •Any finding in the medical examination (including BP, PR or ECG) deviating from normal and assessed as clinically relevant by the investigator at screening visit.
- •Repeated measurement of systolic blood pressure outside the range of 90 to 140 millimetre of mercury (mmHg) , diastolic blood pressure outside the range of 40 to 99 mmHg, or pulse rate outside the range of 40 to 99 beats per minute (bpm) at screening visit.
- •Any laboratory value outside the reference range that the investigator considers to be of clinical relevance at screening visit.
- •Any evidence of a concomitant disease assessed as clinically relevant by the investigator
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
- •Diseases of the central nervous system (including but not limited to any kind of seizures or stroke), and other relevant neurological or psychiatric disorders
- •History of relevant orthostatic hypotension, fainting spells, or blackouts Further exclusion criteria apply.
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo matching BI 1584862
干预措施: Placebo (Drug)
BI 1584862 dose group 1
Experimental
Group receiving dose 1 of BI 1584862
干预措施: BI 1584862 (Drug)
BI 1584862 dose group 2
Experimental
Group receiving dose 2 of BI 1584862
干预措施: BI 1584862 (Drug)
BI 1584862 dose group 3
Experimental
Group receiving dose 3 of BI 1584862
干预措施: BI 1584862 (Drug)
BI 1584862 dose group 4
Experimental
Group receiving dose 4 of BI 1584862
干预措施: BI 1584862 (Drug)
结局指标
主要结局
Occurrence of any treatment-emergent adverse event assessed as drug-related by the investigator
时间窗: Up to day 10
次要结局
- Area under the concentration-time curve of plasma BI 1584862 over the time interval from 0 to the last quantifiable data point (AUC0-tz)(Up to day 4)
- Maximum measured concentration of BI 1584862 in plasma (Cmax)(Up to day 4)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
1 期
This Study is Done in Healthy Japanese Volunteers. It Looks at How Different Doses of BI 705564 Are Taken up in the Body and How Well They Are ToleratedHealthyNCT03747926Boehringer Ingelheim
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of BI 201335 NA in Healthy Male SubjectsHealthyNCT02182297Boehringer Ingelheim50
已完成
1 期
A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are ToleratedHealthyNCT05469646Boehringer Ingelheim24
已完成
1 期
This Study Tests the Safety, Tolerability and How Different Doses of BI 1265162 Are Taken up in the Body of Healthy MenHealthyNCT03349723Boehringer Ingelheim57
已完成
1 期
This Study Tests BI 685509 in Healthy Chinese and Japanese Men; the Study Tests How Different Doses of BI 685509 Are Taken up in the Body and How Well They Are ToleratedHealthyNCT03259464Boehringer Ingelheim72